Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

Milestone triggered for Inventiva
November 2017
SHARING OPTIONS:

DAIX, France—Inventiva recently reported that Boehringer Ingelheim has exercised its option to advance the companies' collaboration, which triggered a €2.5-million milestone payment to Inventiva. A joint research team recently validated a new fibrosis target, and with this option exercise the partners will jointly develop treatments in the selected indication of idiopathic pulmonary fibrosis.
 
“We are excited about moving this very productive and highly interactive collaboration forward, which combines Inventiva’s strong competency and know-how in the field of transcriptional regulation and fibrosis with Boehringer Ingelheim’s expertise in the discovery and development of treatments for fibrotic diseases like IPF,” commented Dr. Clive R. Wood, senior corporate vice president of discovery research at Boehringer Ingelheim “This collaboration with Inventiva is part of Boehringer Ingelheim’s comprehensive research and development focus on fibrotic diseases.”

Back



PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2018 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.